APLS Earnings Prediction
The chart below shows how APLS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, APLS sees a +13.24% change in stock price 10 days leading up to the earnings, and a +3.21% change 10 days following the report. On the earnings day itself, the stock moves by -4.54%. This data can give you a slight idea of what to expect for the next quarter's release.
APLS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
196.83M
78.29%
-1.43%
Gross Margin
82.95%
4.08%
-6.20%
Operating Margin
-24.02%
-79.13%
62.96%
Net Margin
-29.19%
-77.02%
54.77%
EPS
-0.46
-60.68%
53.33%
No Data Available
APLS Earnings Analysis
Apellis Pharmaceuticals, Inc. Common Stock Corporation (APLS.O) Earnings Conference Call
Positive
Impressive Revenue Surge: 1. Strong Revenue Growth: Apellis reported total revenue of approximately $197 million for Q3 2024, a significant increase from $110 million in the same quarter last year, showcasing strong year-over-year growth.
SYFOVRE Demand Surge: 2. Increased Demand for SYFOVRE: Commercial vial demand for SYFOVRE grew by 7% quarter-over-quarter, with 84,500 commercial vials shipped to physicians, reinforcing its market leadership.
High Compliance in Treatment: 3. High Compliance Rate for EMPAVELI: EMPAVELI generated $24.6 million in U.S. product revenue in PNH during Q3 2024, with a remarkable compliance rate of 97%, indicating strong patient adherence to treatment.
VALIANT Study Success: 4. Positive Phase III VALIANT Results: The Phase III VALIANT study results for EMPAVELI in C3G and IC-MPGN demonstrated a statistically significant 68% reduction in proteinuria, highlighting its potential as a best-in-class treatment.
Cash Reserves Strength: 5. Strong Cash Position: Apellis ended Q3 2024 with $397 million in cash and cash equivalents, providing a solid financial foundation to support ongoing operations and future growth initiatives.
Negative
Quarterly Revenue Decline: 1. Revenue Decline: SYFOVRE's net product revenue fell by 1.7% compared to the previous quarter, despite a year-over-year increase of over 100%.
Gross to Net Adjustments: 2. Increased Gross to Net Adjustments: The company experienced higher gross to net adjustments due to strategic contracting decisions, impacting overall net revenue and leading to a significant increase in SYFOVRE's gross to net percentage this quarter.
Flat Revenue Growth Outlook: 3. Flat Revenue Growth Guidance: Apellis anticipates flat to modest net revenue growth in the fourth quarter of 2024, indicating a slowdown in sales momentum.
CHMP Negative Opinion Impact: 4. Negative CHMP Opinion: The company received a negative opinion from the CHMP regarding SYFOVRE, leading to a halt in pursuing EU approval, which could limit market expansion.
Quarterly Net Loss: 5. Net Loss: Apellis reported a net loss of $57.4 million for the third quarter, reflecting ongoing financial challenges despite revenue growth.
APLS FAQs
How does APLS typically perform around its earnings report dates?
Is Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
APLS Earning Call Sentiment
Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
APLS.O
-3.27%Positive
The earnings call reflects mixed signals. Strong revenue growth and market leadership for SYFOVRE are positive, but the lack of guidance and vague responses on key metrics like gross to net adjustments create uncertainty. The absence of a shareholder return plan and the impact of economic factors on revenue are additional concerns. While there is potential for market expansion, the competitive landscape and contracting decisions temper enthusiasm. Overall, the sentiment is neutral, with no strong catalysts to drive significant short-term stock price movement.
